摘要
目的观察多西紫杉醇联合替吉奥治疗蒽环类耐药晚期三阴乳腺癌(TNBC)的临床疗效和毒副反应。方法采用多西紫杉醇联合替吉奥治疗46例蒽环类耐药的晚期TNBC患者,3周为1周期,治疗2周期后评价疗效及毒副反应。结果 46例患者中,CR 1例,PR 15例,SD 18例,PD 12例,有效率34.8%,疾病控制率73.9%。主要毒副反应为骨髓抑制和胃肠道反应,无化疗相关死亡患者。结论多西紫杉醇联合替吉奥治疗蒽环类耐药晚期TNBC有效,毒副反应轻,患者耐受性好。
Objective To observe the efficacy and toxicities of docetaxel combined with S-1 in the treatment of anthracycline-resistant advanced triple-negative breast cancer （TNBC）. Methods Forty-six patients with anthracycline-resistant advanced TNBC were treated with docetaxel and S-l, every 3 weeks were 1 cycle,the efficacy and toxicities were evaluated after 2 cycles. Results Of the 46 patients, CR was observed in the 1 case,PR in the 15 cases, SD in the 18 cases, PD in the 12 cases, the response rate was 34.8 %, the disease control rate was 73.9%. The main toxicities were bone marrow suppression and gastrointestinal reaction, no chemotherapy-related death was observed. Conclusion Docetaxel combined with S-1 is effective and safe for anthracycline-resistant advanced TNBC.
出处
《肿瘤基础与临床》
2013年第4期298-300,共3页
journal of basic and clinical oncology
